Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study

Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between low natalizumab receptor occupancy and subjective wearing-off symptoms at t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the neurological sciences 2020-08, Vol.415, p.116880-116880, Article 116880
Hauptverfasser:	Bringeland, Gerd Haga, Myhr, Kjell-Morten, Vedeler, Christian Alexander, Gavasso, Sonia
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Follow-Up Studies Humans Immunologic Factors - therapeutic use Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab Natalizumab - therapeutic use Prospective Studies Receptor occupancy Relapsing-remitting multiple sclerosis Treatment response Wearing-off
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!